Joint Formulary & PAD

Alfuzosin hydrochloride - Benign prostatic hyperplasia

You are here : Home > Formulary Search > Alfuzosin hydrochloride - Benign prostatic hyperplasia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Modified release tablets
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
Important
2nd or 3rd line. Tamsulosin MR capsules or Doxazosin immediate release tablets are preferred

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Alfuzosin hydrochloride
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary retention
Brand Names Include :
Xatral, Vasran, Zochek, Besavar
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

06 Dec 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option

  • Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
  • Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)

Alfuzosin is more costly and is therefore not recommended as a 1st-line option. (NOTE - prescribe generically).

Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups

Other Indications

Below are listed other indications that Alfuzosin hydrochloride is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Benign prostatic hyperplasia.